Leukemia Research
Volume 29, Issue 8 , Pages 971-973 , August 2005

Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) Outcome of discontinuation of imatinib therapy after achieving a molecular remission

  • Rıdvan Ali

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 224 4428400; fax: +90 224 4428060.
    • ,
  • Fahir Özkalemkaş

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Tülay Özçelik

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Vildan Özkocaman

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Ülkü Ozan

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Yalçın Kimya

      Affiliations

    • Department of Obstetrics and Gynecology, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Nilgün Köksal

      Affiliations

    • Division of Neonatology, Department of Pediatrics, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Tuna Gülten

      Affiliations

    • Department of Medical Genetics, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Tahsin Yakut

      Affiliations

    • Department of Medical Genetics, Uludag University School of Medicine, Bursa, Turkey
    • ,
  • Ahmet Tunalı

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey

Received 1 January 2005

References 

  1. Ali R, Özkalemkas F, Özkocaman V, Özçelik T, Ozan Ü, Kimya Y, et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol. 2004;34:215–217
  2. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28S1:S71–S73
  3. Cortes J, O’Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204–2205
  4. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40:21–25
  5. Ali R, Özkalemkaş F, Özkocaman V, Bülbül-Başkan E, Özçelik T, Ozan Ü, et al. Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukapheresis. Ann Hematol. 2004;83:61–63
  6. Ali R, Özkalemkas F, Özçelik T, Özkocaman V, Ozan Ü, Kimya Y, et al. Maternal and fetal outcomes in pregnancy complicated with acute leukemia: a single institutional experience with 10 pregnancies at 16 years. Leuk Res. 2003;27:381–385
  7. Heartın E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukemia treated with Imatinib. Leuk Lymphoma. 2004;45:1307–1308
  8. Glivec-Clinical monograph. Basel, Switzerland: Novartis Pharma AG; 2004.
  9. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283–291
  10. Buerkers TE, Lallas TA. Chemotherapy in pregnancy. Obstet Gynecol Clin North Am. 1998;25:323–329

PII: S0145-2126(05)00053-6

doi: 10.1016/j.leukres.2005.01.009

Leukemia Research
Volume 29, Issue 8 , Pages 971-973 , August 2005

Article Tools